Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Newswire.ca - Thu Nov 14, 4:00PM CST

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 Newswire.ca - Wed Nov 13, 4:00PM CST

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Newswire.ca - Tue Nov 12, 4:56PM CST

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results Newswire.ca - Thu Nov 7, 4:00PM CST

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million Newswire.ca - Thu Oct 31, 6:36PM CDT

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
BRE.TO : 15.30 (-2.11%)
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 Newswire.ca - Mon Oct 28, 6:00AM CDT

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis Newswire.ca - Tue Oct 15, 6:00AM CDT

Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 Newswire.ca - Thu Oct 10, 6:00AM CDT

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Strengthens Senior Management Team Newswire.ca - Wed Oct 2, 4:01PM CDT

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases Newswire.ca - Thu Sep 19, 4:00PM CDT

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)

Barchart Exclusives

Leverage the J-Hook Pattern for a Possible 122% Payout in EOG Resources (EOG) Barchart - 3 minutes ago
With fundamentals aligning favorably with the technicals, hydrocarbon energy play EOG stock should be on the speculator’s radar. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot